BIB vs. ARKG
Compare and contrast key facts about ProShares Ultra Nasdaq Biotechnology (BIB) and ARK Genomic Revolution Multi-Sector ETF (ARKG).
BIB and ARKG are both exchange-traded funds (ETFs), meaning they are traded on stock exchanges and can be bought and sold throughout the day. BIB is a passively managed fund by ProShares that tracks the performance of the NASDAQ Biotechnology Index (200%). It was launched on Apr 7, 2010. ARKG is an actively managed fund by ARK. It was launched on Oct 31, 2014.
Performance
BIB vs. ARKG - Performance Comparison
Loading graphics...
BIB vs. ARKG - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
BIB ProShares Ultra Nasdaq Biotechnology | 3.51% | 59.21% | -9.84% | -1.06% | -28.85% | -6.02% | 39.79% | 46.71% | -24.93% | 40.49% |
ARKG ARK Genomic Revolution Multi-Sector ETF | -6.49% | 23.04% | -28.24% | 16.22% | -53.90% | -33.92% | 180.40% | 44.00% | -1.26% | 46.61% |
Returns By Period
In the year-to-date period, BIB achieves a 3.51% return, which is significantly higher than ARKG's -6.49% return. Over the past 10 years, BIB has outperformed ARKG with an annualized return of 6.98%, while ARKG has yielded a comparatively lower 4.95% annualized return.
BIB
- 1D
- 1.31%
- 1M
- -5.43%
- YTD
- 3.51%
- 6M
- 32.05%
- 1Y
- 82.75%
- 3Y*
- 16.12%
- 5Y*
- 0.02%
- 10Y*
- 6.98%
ARKG
- 1D
- 2.54%
- 1M
- -9.43%
- YTD
- -6.49%
- 6M
- -6.10%
- 1Y
- 34.11%
- 3Y*
- -3.42%
- 5Y*
- -21.16%
- 10Y*
- 4.95%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
BIB vs. ARKG - Expense Ratio Comparison
BIB has a 0.95% expense ratio, which is higher than ARKG's 0.75% expense ratio.
Return for Risk
BIB vs. ARKG — Risk / Return Rank
BIB
ARKG
BIB vs. ARKG - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for ProShares Ultra Nasdaq Biotechnology (BIB) and ARK Genomic Revolution Multi-Sector ETF (ARKG). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| BIB | ARKG | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 1.78 | 0.77 | +1.01 |
Sortino ratioReturn per unit of downside risk | 2.29 | 1.38 | +0.91 |
Omega ratioGain probability vs. loss probability | 1.29 | 1.16 | +0.13 |
Calmar ratioReturn relative to maximum drawdown | 3.35 | 1.11 | +2.24 |
Martin ratioReturn relative to average drawdown | 11.88 | 2.98 | +8.90 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading graphics...
Sharpe Ratios by Period
| BIB | ARKG | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 1.78 | 0.77 | +1.01 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.00 | -0.47 | +0.47 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.15 | 0.12 | +0.03 |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.35 | 0.08 | +0.26 |
Correlation
The correlation between BIB and ARKG is 0.78, which is considered to be high. That indicates a strong positive relationship between their price movements. Having highly-correlated positions in a portfolio may signal a lack of diversification, potentially leading to increased risk during market downturns.
Dividends
BIB vs. ARKG - Dividend Comparison
BIB's dividend yield for the trailing twelve months is around 0.60%, while ARKG has not paid dividends to shareholders.
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
BIB ProShares Ultra Nasdaq Biotechnology | 0.60% | 0.77% | 1.69% | 0.07% | 0.03% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
ARKG ARK Genomic Revolution Multi-Sector ETF | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.62% | 0.85% | 3.14% | 0.82% | 1.34% |
Drawdowns
BIB vs. ARKG - Drawdown Comparison
The maximum BIB drawdown since its inception was -67.24%, smaller than the maximum ARKG drawdown of -83.59%. Use the drawdown chart below to compare losses from any high point for BIB and ARKG.
Loading graphics...
Drawdown Indicators
| BIB | ARKG | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -67.24% | -83.59% | +16.35% |
Max Drawdown (1Y)Largest decline over 1 year | -21.73% | -27.51% | +5.78% |
Max Drawdown (5Y)Largest decline over 5 years | -65.86% | -80.18% | +14.32% |
Max Drawdown (10Y)Largest decline over 10 years | -66.20% | -83.59% | +17.39% |
Current DrawdownCurrent decline from peak | -23.89% | -75.76% | +51.87% |
Average DrawdownAverage peak-to-trough decline | -32.84% | -35.32% | +2.48% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 6.13% | 10.24% | -4.11% |
Volatility
BIB vs. ARKG - Volatility Comparison
ProShares Ultra Nasdaq Biotechnology (BIB) has a higher volatility of 16.73% compared to ARK Genomic Revolution Multi-Sector ETF (ARKG) at 13.41%. This indicates that BIB's price experiences larger fluctuations and is considered to be riskier than ARKG based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading graphics...
Volatility by Period
| BIB | ARKG | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 16.73% | 13.41% | +3.32% |
Volatility (6M)Calculated over the trailing 6-month period | 28.82% | 31.90% | -3.08% |
Volatility (1Y)Calculated over the trailing 1-year period | 47.20% | 44.84% | +2.36% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 43.32% | 45.39% | -2.07% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 46.77% | 40.94% | +5.83% |